TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7736528

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies against CA125
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies against TAG72
Number of subjects: 58
Study: 2758104

Group type: EXPERIMENTAL
Intervention: Arbaprostil (50 micrograms) and Aspirin (975 mg) coadministration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (975 mg) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arbaprostil (50 micrograms) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salicylate pharmacokinetics
Number of subjects: 0
Study: 8049998

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy or chemoradiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment
Number of subjects: 0
Study: 676309

Group type: EXPERIMENTAL
Intervention: Daily administration of 1200 IU vitamin D3
Number of subjects: 21

Group type: COMPARATOR
Intervention: Single oral dose of 200,000 IU vitamin D3
Number of subjects: 21
Study: 30670010

Group type: EXPERIMENTAL
Intervention: Amla extract (500 mg) administered twice daily for 12 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 27193080

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (1.5 mcg/kg) + intravenous tramadol (2 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous tramadol (2 mg/kg)
Number of subjects: 20
Study: 27465265

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3876

Group type: EXPERIMENTAL
Intervention: Pioglitazone (in patients with initial impaired fasting glucose)
Number of subjects: 3876

Group type: EXPERIMENTAL
Intervention: Pioglitazone (in patients with elevated HbA1c)
Number of subjects: 3876
Study: 25311995

Group type: EXPERIMENTAL
Intervention: Ivacaftor 150 mg every 12 hours
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 23090145

Group type: EXPERIMENTAL
Intervention: RNMB present (train-of-four ratio < 0.9)
Number of subjects: 150

Group type: COMPARATOR
Intervention: RNMB absent (train-of-four ratio ≥ 0.9)
Number of subjects: 150
Study: 19695596

Group type: EXPERIMENTAL
Intervention: Urodynamic studies for urge syndrome
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Urodynamic studies for dysfunctional voiding
Number of subjects: 202
Study: 17878730

Group type: EXPERIMENTAL
Intervention: Prolonged and exclusive breast-feeding promotion intervention
Number of subjects: 17046

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 17046
Study: 15354916

Group type: EXPERIMENTAL
Intervention: 30 mL of 0.5% bupivacaine with 1:200,000 epinephrine and 1 microg/kg of clonidine
Number of subjects: 64

Group type: COMPARATOR
Intervention: 30 mL of 0.5% bupivacaine with 1:200,000 epinephrine (control group)
Number of subjects: 64
Study: 11254844

Group type: EXPERIMENTAL
Intervention: Fenoldopam, 0.1 microg/kg/min
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 9823809

Group type: EXPERIMENTAL
Intervention: Diathermy dissection
Number of subjects: 91

Group type: COMPARATOR
Intervention: Scissors dissection
Number of subjects: 91
Study: 8210255

Group type: EXPERIMENTAL
Intervention: CPT-11 (100 mg/m2 weekly intravenous infusion, regimen A)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: CPT-11 (150 mg/m2 every two weeks, regimen B)
Number of subjects: 61
Study: 2816967

Group type: EXPERIMENTAL
Intervention: Low-antigen-content diet (LAC diet)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard normocaloric diet (placebo)
Number of subjects: 24
Study: 802630

Group type: EXPERIMENTAL
Intervention: Diuretic plus methyldopa
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diuretic alone
Number of subjects: 20
Study: 31461306

Group type: EXPERIMENTAL
Intervention: MSE group (tooth bone‐borne expander)
Number of subjects: 48

Group type: COMPARATOR
Intervention: C-expander group (tissue bone‐borne expander)
Number of subjects: 48
Study: 29065278

Group type: EXPERIMENTAL
Intervention: 3 mg·kg‐1 body mass caffeine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6 mg·kg‐1 body mass caffeine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 26694130

Group type: EXPERIMENTAL
Intervention: G-CSF (5 μg/kg/d Lenograstim from day 2 after each course of six chemotherapy courses)
Number of subjects: 58

Group type: COMPARATOR
Intervention: G-CSF- (no G-CSF administration)
Number of subjects: 58
Study: 24886606

Group type: EXPERIMENTAL
Intervention: Theory-based behaviour change intervention
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study: 21773849

Group type: EXPERIMENTAL
Intervention: Hospital Medicine Physician Worklife Survey
Number of subjects: 816
Study: 20089755

Group type: EXPERIMENTAL
Intervention: Packed lunches
Number of subjects: 1294
Study: 18349272

Group type: COMPARATOR
Intervention: Flavonoid intake (fourth quartile)
Number of subjects: 27111

Group type: COMPARATOR
Intervention: Flavonoid intake (first quartile)
Number of subjects: 27111

Group type: COMPARATOR
Intervention: Supplemental alpha-tocopherol (50 mg/d) and/or beta-carotene (20 mg/d)
Number of subjects: 27111

Group type: COMPARATOR
Intervention: Flavonols, flavan-3-ols, kaempferol, quercetin, catechin, and epicatechin
Number of subjects: 27111
Study: 15984021

Group type: EXPERIMENTAL
Intervention: Creatine (5 gm/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Glutamine (0.6 gm/kg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Creatine and Glutamine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Creatine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 14623176

Group type: EXPERIMENTAL
Intervention: Immuno-Guard
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Colchicine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group C
Number of subjects: 36
Study: 10634837

Group type: EXPERIMENTAL
Intervention: Early sodium supplementation (4 mmol/kg/day starting on day 2 after birth)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Delayed sodium supplementation (4 mmol/kg/day starting after 6% weight loss)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Early sodium supplementation
Number of subjects: 46
Study: 8800584

Group type: EXPERIMENTAL
Intervention: Coffee drinking in normotensives (NT)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Abstaining from caffeine in untreated hypertensives (UNHT)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Tea drinking in treated hypertensives (TRHT)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Coffee drinking in untreated hypertensives (UNHT)
Number of subjects: 171
Study: 1281650

Group type: EXPERIMENTAL
Intervention: Initial chemotherapy with sequential methotrexate‐5‐FU with leucovorin rescue (MFL) for 6 months
Number of subjects: 183

Group type: COMPARATOR
Intervention: Primary expectancy with chemotherapy only after the appearance of symptoms
Number of subjects: 183
Study: 3977555

Group type: EXPERIMENTAL
Intervention: 0.75 mL/kg of ethanol
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 1.1 mL/kg of ethanol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 31027883

Group type: EXPERIMENTAL
Intervention: Sevelamer (1,600 mg thrice daily) for 3 months
Number of subjects: 53

Group type: COMPARATOR
Intervention: No sevelamer for 3 months
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sevelamer treatment
Number of subjects: 53
Study: 30075908

Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX
Number of subjects: 124

Group type: COMPARATOR
Intervention: Gemcitabine plus nab-paclitaxel (GnP)
Number of subjects: 124
Study: 26947315

Group type: EXPERIMENTAL
Intervention: Virtual reality treadmill training (VRTT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Treadmill training (TT)
Number of subjects: 18
Study: 24671450

Group type: EXPERIMENTAL
Intervention: TAK-442 (pooled doses)
Number of subjects: 2753

Group type: EXPERIMENTAL
Intervention: TAK-442 (modified ISTH scale)
Number of subjects: 2753

Group type: EXPERIMENTAL
Intervention: TAK-442 (various doses)
Number of subjects: 2753

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2753
Study: 22348233

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1 mg/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 21809603

Group type: EXPERIMENTAL
Intervention: Injectable lidocaine 2% solution (1.5 ml)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Topical lidocaine 2% gel (1.5 ml)
Number of subjects: 61
Study: 18413426

Group type: EXPERIMENTAL
Intervention: 2,000 IU oral vitamin D2 daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D2 weekly
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2,000 IU vitamin D3 daily
Number of subjects: 40
Study: 15710045

Group type: EXPERIMENTAL
Intervention: Anti-Hsp60
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Anti-Hsp70
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Anti-Hsp60 and Anti-Hsp70 levels
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Family history of asthma
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Total immunoglobulin E and interleukin-4 levels
Number of subjects: 95
Study: 11831538

Group type: EXPERIMENTAL
Intervention: ERA-923 (10-200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ERA-923
Number of subjects: 0
Study: 10709536

Group type: EXPERIMENTAL
Intervention: Nocturnal bite plate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 9
Study: 7851575

Group type: EXPERIMENTAL
Intervention: PTFE (Gore-Tex Surgical Membrane)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (uncovered sites)
Number of subjects: 27
Study: 1682643

Group type: EXPERIMENTAL
Intervention: monocomponent pertussis toxoid vaccine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: two-component acellular vaccine also containing filamentous haemagglutinin
Number of subjects: 73

Group type: COMPARATOR
Intervention: 20% albumin solution (placebo)
Number of subjects: 73
Study: 6756799

Group type: EXPERIMENTAL
Intervention: Oxipor VHC lotion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tegrin lotion
Number of subjects: 0
Study: 31146090

Group type: EXPERIMENTAL
Intervention: Gesture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not gesture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual interference task
Number of subjects: 0
Study: 29074513

Group type: EXPERIMENTAL
Intervention: HelpMeDoIt! app/website intervention for 12 months with social support from nominated helpers.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Leaflet on healthy lifestyle (control group).
Number of subjects: 120
Study: 25673560

Group type: EXPERIMENTAL
Intervention: RSV detected in ILI episodes
Number of subjects: 6266

Group type: EXPERIMENTAL
Intervention: Incidence of RSV-associated ILI
Number of subjects: 6266

Group type: EXPERIMENTAL
Intervention: Hospitalization due to ILI episodes
Number of subjects: 6266

Group type: EXPERIMENTAL
Intervention: Incidence of RSV-associated ILI resulting in medical attendance
Number of subjects: 6266
Study: 24351402

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing containing ceramide (arm A)
Number of subjects: 33

Group type: COMPARATOR
Intervention: 10% urea cream (arm B)
Number of subjects: 33
Study: 22943933

Group type: EXPERIMENTAL
Intervention: Mirabegron (oral dosing 25 - 150 mg)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Mirabegron (i.v. dosing 7.5 - 50 mg)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Mirabegron (oral dosing)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Mirabegron (i.v. dosing)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Mirabegron (oral and i.v. dosing)
Number of subjects: 103
Study: 19446846

Group type: EXPERIMENTAL
Intervention: High-nutrient diet
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard-nutrient diet
Number of subjects: 95
Study: 17476705

Group type: EXPERIMENTAL
Intervention: Tiagabine 4-16 mg per day for 12 weeks
Number of subjects: 54
Study: 15148924

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Levofloxacin, terazosin and microwave
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Levofloxacin, Chinese traditional medicine and microwave
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control Group (not explicitly mentioned)
Number of subjects: 72
Study: 12171964

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (12 billion colony forming units)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG and Placebo
Number of subjects: 37
Study: 9614307

Group type: EXPERIMENTAL
Intervention: Liquid meal
Number of subjects: 6

Group type: COMPARATOR
Intervention: Solid meal
Number of subjects: 6

Group type: COMPARATOR
Intervention: Soups with differing fat saturation
Number of subjects: 6
Study: 9536926

Group type: EXPERIMENTAL
Intervention: NG‐monomethyl L‐arginine (3 mg h‐1 kg‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1990984

Group type: EXPERIMENTAL
Intervention: Generic topical steroids
Number of subjects: 6

Group type: COMPARATOR
Intervention: Trade-name topical steroids
Number of subjects: 6
Study: 6337004

Group type: EXPERIMENTAL
Intervention: Epoprostenol (PGI2) infusion at doses of 2, 4, 6, and 8 ng/kg/min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dipyridamole (400 mg/day for 3 days)
Number of subjects: 0
Study: 31926328

Group type: EXPERIMENTAL
Intervention: Minimally invasive treatment (endoscopic approach)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Conventional Bascom cleft lift treatment
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Cost analysis of minimally invasive treatment
Number of subjects: 145
Study: 30474448

Group type: COMPARATOR
Intervention: Intensity-modulated proton therapy (IMPT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Tomotherapy (TOMO)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 25
Study: 30739899

Group type: EXPERIMENTAL
Intervention: Barbershop Talk with Brothers (BTWB) project
Number of subjects: 860
Study: 27117045

Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 51

Group type: COMPARATOR
Intervention: Minimal effort walking
Number of subjects: 51
Study: 24190860

Group type: EXPERIMENTAL
Intervention: High-dose n-3 PUFA (Lovaza 3600 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose n-3 PUFA (Lovaza 900 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22569895

Group type: EXPERIMENTAL
Intervention: VD(3) encapsulated in rCM, 50,000 IU, in 1% fat milk
Number of subjects: 87

Group type: COMPARATOR
Intervention: Tween‐80 emulsified VD(3)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Unencapsulated VD(3)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: VD(3) encapsulated in rCM after ultra-high-pressure homogenization
Number of subjects: 87
Study: 20483364

Group type: COMPARATOR
Intervention: NoGo-switch (Go/NoGo)
Number of subjects: 24

Group type: COMPARATOR
Intervention: NoGo-repeat (NoGo/NoGo)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NoGo-N200
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Go-trials
Number of subjects: 24
Study: 17337426

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 100 mg oral treatment
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (non diabetic males)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Non neuropathic diabetic patients
Number of subjects: 150
Study: 15778966

Group type: EXPERIMENTAL
Intervention: Three-dose hepatitis B vaccination course (Engerix B GlaxoSmithKline) administered at 0, 1, and 12 months; adult dose containing 20 mug recombinant hepatitis B surface antigen in 1 ml suspension.
Number of subjects: 528
Study: 12224782

Group type: EXPERIMENTAL
Intervention: Nonsmokers exposed to cigarette smoke
Number of subjects: 848

Group type: COMPARATOR
Intervention: Nonsmokers not exposed to smoke
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Passive smoking
Number of subjects: 848
Study: 9295239

Group type: EXPERIMENTAL
Intervention: Isoniazid daily for six months
Number of subjects: 2736

Group type: EXPERIMENTAL
Intervention: Isoniazid and rifampin daily for three months
Number of subjects: 2736

Group type: EXPERIMENTAL
Intervention: Isoniazid, rifampin, and pyrazinamide daily for three months
Number of subjects: 2736

Group type: COMPARATOR
Intervention: Isoniazid for six months
Number of subjects: 2736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2736
Study: 7509573

Group type: EXPERIMENTAL
Intervention: Structured sensorimotor therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Child-centered therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both therapies
Number of subjects: 12
Study: 3539030

Group type: EXPERIMENTAL
Intervention: 20 micrograms intranasal DDAVP
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 20 micrograms DDAVP during school journeys or holidays
Number of subjects: 17
Study: 30358181

Group type: EXPERIMENTAL
Intervention: Speeded intervention (n=211)
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Nonspeeded intervention (n=204)
Number of subjects: 639

Group type: COMPARATOR
Intervention: Control group (n=224)
Number of subjects: 639
Study: 29680359

Group type: EXPERIMENTAL
Intervention: 6 meals/day
Number of subjects: 47

Group type: COMPARATOR
Intervention: 3 meals/day
Number of subjects: 47
Study: 27333895

Group type: EXPERIMENTAL
Intervention: Pictorial warnings
Number of subjects: 1413

Group type: COMPARATOR
Intervention: Text warnings
Number of subjects: 1413

Group type: EXPERIMENTAL
Intervention: Reactance factors (anger, exaggeration, government, manipulation, personal attack)
Number of subjects: 1413
Study: 23531574

Group type: EXPERIMENTAL
Intervention: Occupational health care management program (OHMP) focusing on self-efficacy and self-management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group 2
Number of subjects: 0
Study: 22236849

Group type: EXPERIMENTAL
Intervention: Intervention centres with child TB guidelines, training, and logistics support
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control centres with usual practice
Number of subjects: 36
Study: 20236776

Group type: EXPERIMENTAL
Intervention: Vaginal oestradiol (25 micrograms, Vagifem, Novo Nordisk) once daily for 2 weeks, then twice weekly for 6 months (group 1)
Number of subjects: 190

Group type: COMPARATOR
Intervention: TVT-O procedure only (group 2)
Number of subjects: 190
Study: 18768943

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 2521

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 2521

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 2521
Study: 15866552

Group type: EXPERIMENTAL
Intervention: Naltrexone alone
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Disulfiram and naltrexone (open-label disulfiram and blinded naltrexone)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Disulfiram and placebo (open-label disulfiram and blinded placebo)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 254
Study: 12872170

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Thiopental and isoflurane
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Thiopental, nitrous oxide, and low-dose isoflurane
Number of subjects: 90
Study: 10537257

Group type: EXPERIMENTAL
Intervention: UHR system (Osteonics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All bipolar prostheses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Some prostheses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bipolar endoprostheses
Number of subjects: 0
Study: 8927680

Group type: EXPERIMENTAL
Intervention: Zotepine (150 to 300 mg)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Haloperidol (10 to 20 mg)
Number of subjects: 126
Study: 1294919

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 70-80 micrograms/hr
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 90-100 micrograms/hr
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intramuscular morphine 150 micrograms/kg every 6h
Number of subjects: 21
Study: 6364994

Group type: EXPERIMENTAL
Intervention: 1% sulconazole cream
Number of subjects: 192

Group type: COMPARATOR
Intervention: 2% miconazole cream
Number of subjects: 192
Study: 31140355

Group type: EXPERIMENTAL
Intervention: IVT + EVT
Number of subjects: 1485

Group type: COMPARATOR
Intervention: EVT alone
Number of subjects: 1485
Study: 26663743

Group type: EXPERIMENTAL
Intervention: Obese victim and nonobese perpetrator scenario
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obese perpetrator and nonobese victim scenario
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both victim and perpetrator described as obese
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obese victim scenario
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obese perpetrator scenario
Number of subjects: 0
Study: 26891677

Group type: EXPERIMENTAL
Intervention: Lower MAP target (60-65 mmHg)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Higher MAP target (75-80 mmHg)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Lower MAP target (60-65 mmHg) among patients aged 75 years or older
Number of subjects: 118

Group type: COMPARATOR
Intervention: Higher MAP target (75-80 mmHg) among patients aged 75 years or older
Number of subjects: 118
Study: 24901490

Group type: EXPERIMENTAL
Intervention: Limbal‐conjunctival autograft with mitomycin C (MMC+)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Limbal‐conjunctival autograft without mitomycin C (MMC-)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups (MMC+ and MMC-)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Preoperative corneal astigmatism (PRCA)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Threshold for astigmatism reduction
Number of subjects: 68